Usual Adult Dose for Diabetes Type 2:
Immediate-release (Byetta): Initial dose: 5 mcg subcutaneously twice a day within the 60-minute period before the morning and evening meals -Maintenance dose: After 1 month, may increase dose to 10 mcg subcutaneously twice a day based on clinical response-Maximum dose: 10 mcg twice a day-Alternatively, may give before the two main meals of the day provided dosing is 6 hours or more apartExtended-release (Bydureon; Bydureon BCISE): Initial dose: 2 mg subcutaneously once every 7 days (weekly) -May administer any time of day, with or without meals; see dose adjustments for information on missed doses and changing administration day -Prior treatment with immediate-release product is not required; for patients who do switch, discontinue immediate-release at initiation of extended-release; transient blood glucose elevations may occur for approximately 2 to 4 weeks after switch-Switching extended-release products may be done at next regularly scheduled doseComments:-This drug has not been studied in patients with a history of pancreatitis and therefore, other therapies should be considered in these patients.  -Extended-release exenatide is not recommended as first-line therapy because of the uncertainty of the risk of thyroid C-cell tumors.  -Patients may experience transient (approximately 2 to 4 weeks) elevation in blood sugar when switching from immediate-release exenatide to extended-release.   Use: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
 Detailed Exenatide dosage information
